English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

CLN-IgG (Pritumumab) is the natural human monoclonal antibody recognizing the altered-vimentin expressed on ectosomes of malignant cells. Comparative analysis of the sequelogous complementarity determining regions of the five anti-idiotypic antibodies to the paratope of CLN-IgG implied that the core epitope found in vimentin possessed prionogenic potential to form coacervates tending to amyloidosis, which are called vimentin prionogenic idiotope determining amino acids motif (vipidam). Sets of the sequelog of vipidam were found in countless prions and prion-like proteins. CLN-IgG carries over the sequelog of vipidam in its paratope, which was found not only in 14-3-3 proteins but also in α-synuclein. The effectiveness of Pritumumab on brain tumor regression was inferred by its intervention on vimentin prionogenesis via a prion silencing mechanism attributed to the chaperonic antibody like CLN-IgG (Pritumumab).

british journal of cancer research

Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant-associated autologous anti-vimentin antibody, CLN-IgG (Pritumumab)